-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tisagenlecleucel in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tisagenlecleucel in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tisagenlecleucel in Primary Mediastinal B-Cell Lymphoma Drug Details: Tisagenlecleucel...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSE-279 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OSE-279 in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OSE-279 in Hepatocellular Carcinoma Drug Details: OSE-279 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSE-279 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OSE-279 in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OSE-279 in Sarcomas Drug Details: OSE-279 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSE-279 in Anal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OSE-279 in Anal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OSE-279 in Anal Cancer Drug Details: OSE-279 is under development for...
-
Product Insights
Anal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anal Cancer - Drugs In Development, 2023’, provides an overview of the Anal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Sicca Syndrome (Sjogren) – Drugs In Development, 2023
Global Markets Direct’s, ‘Sicca Syndrome (Sjogren) - Drugs In Development, 2023’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Primary Sjogren’s Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Sjogren's Syndrome - Drugs In Development, 2023’, provides an overview of the Primary Sjogren's Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Sjogren's Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Goiter – Drugs In Development, 2023
Global Markets Direct’s, ‘Goiter - Drugs In Development, 2023’, provides an overview of the Goiter pipeline landscape. The report provides comprehensive information on the therapeutics under development for Goiter, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Graves Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Graves Diseases - Drugs In Development, 2023’, provides an overview of the Graves Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graves Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveitis - Drugs In Development, 2023’, provides an overview of the Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...